<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00000819</url>
  </required_header>
  <id_info>
    <org_study_id>ACTG 271</org_study_id>
    <secondary_id>11247</secondary_id>
    <nct_id>NCT00000819</nct_id>
  </id_info>
  <brief_title>A Phase II Randomized, Double-Blind, Placebo-Controlled Trial to Determine the Efficacy of Prednisone Therapy in HIV-Associated Nephropathy (HIVAN)</brief_title>
  <official_title>A Phase II Randomized, Double-Blind, Placebo-Controlled Trial to Determine the Efficacy of Prednisone Therapy in HIV-Associated Nephropathy (HIVAN)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Upjohn</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <brief_summary>
    <textblock>
      To determine the efficacy and safety of prednisone in patients with HIV-associated&#xD;
      nephropathy. To determine the effects of prednisone on serum creatinine, urinary protein, and&#xD;
      creatinine clearance.&#xD;
&#xD;
      HIV-associated nephropathy is characterized by heavy proteinuria, rapidly progressive renal&#xD;
      insufficiency, and distinct nephropathologic changes. The syndrome most often occurs in&#xD;
      patients with advanced HIV disease. Little is known about the effects of corticosteroids on&#xD;
      the progression of HIV disease. In light of the possible beneficial effects of&#xD;
      corticosteroids on HIV-associated nephropathy, a controlled trial using prednisone is&#xD;
      warranted.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      HIV-associated nephropathy is characterized by heavy proteinuria, rapidly progressive renal&#xD;
      insufficiency, and distinct nephropathologic changes. The syndrome most often occurs in&#xD;
      patients with advanced HIV disease. Little is known about the effects of corticosteroids on&#xD;
      the progression of HIV disease. In light of the possible beneficial effects of&#xD;
      corticosteroids on HIV-associated nephropathy, a controlled trial using prednisone is&#xD;
      warranted.&#xD;
&#xD;
      Patients are randomized to receive prednisone or placebo for 11 weeks, followed by 13 weeks&#xD;
      of observation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <completion_date type="Actual">September 1996</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment>54</enrollment>
  <condition>HIV Infections</condition>
  <condition>AIDS-Associated Nephropathy</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Patients must have:&#xD;
&#xD;
          -  HIV infection.&#xD;
&#xD;
          -  Biopsy-confirmed glomerulosclerosis and/or mesangial proliferation within 90 days&#xD;
             prior to study entry.&#xD;
&#xD;
          -  Mild to severe renal insufficiency that is stable or worsening.&#xD;
&#xD;
          -  No AIDS-defining opportunistic infections or malignancies.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Co-existing Condition:&#xD;
&#xD;
        Patients with the following symptoms or conditions are excluded:&#xD;
&#xD;
          -  Poorly controlled hypertension or diabetes mellitus.&#xD;
&#xD;
          -  Peptic ulcer disease with gastrointestinal bleeding.&#xD;
&#xD;
          -  Active symptomatic bacterial, protozoal, fungal, or viral infections (other than HIV&#xD;
             disease).&#xD;
&#xD;
          -  Superimposed renal disease that is due to processes other than focal&#xD;
             glomerulosclerosis or mesangial proliferation, including but not limited to&#xD;
             obstructive uropathy, acute tubular necrosis, and prerenal azotemia.&#xD;
&#xD;
          -  Emotional problems sufficient to prevent adequate compliance with study therapy.&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  IV amphotericin B.&#xD;
&#xD;
          -  IV aminoglycosides.&#xD;
&#xD;
          -  IV foscarnet.&#xD;
&#xD;
          -  IV pentamidine.&#xD;
&#xD;
          -  Trimethoprim &gt; 200 mg/day.&#xD;
&#xD;
          -  Nonsteroidal anti-inflammatory agents.&#xD;
&#xD;
          -  Angiotensin converting enzyme inhibitors (benzapril, captopril, enalapril, fosinopril,&#xD;
             lisinopril, guinapril, and ramipril) except for refractory hypertension.&#xD;
&#xD;
        Concurrent Treatment:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Iodinated radiocontrast dye.&#xD;
&#xD;
        Patients with the following prior conditions are excluded:&#xD;
&#xD;
          -  Active pulmonary disease on chest radiograph within 60 days prior to study entry.&#xD;
&#xD;
          -  CMV retinitis on ophthalmologic evaluation within 60 days prior to study entry.&#xD;
&#xD;
          -  Positive blood culture for mycobacteria 10-60 days prior to study entry.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Prior corticosteroid therapy for HIVAN.&#xD;
&#xD;
          -  Corticosteroid therapy for any indication within 30 days prior to study entry.&#xD;
&#xD;
          -  Continuous nonsteroidal anti-inflammatory agents for more than 15 days during the 4&#xD;
             weeks prior to study entry.&#xD;
&#xD;
        Prior Treatment:&#xD;
&#xD;
        Excluded within 30 days prior to study entry:&#xD;
&#xD;
          -  Dialysis for acute or chronic renal failure.&#xD;
&#xD;
          -  Iodinated radiocontrast dye.&#xD;
&#xD;
        Required:&#xD;
&#xD;
          -  Stable antiretroviral therapy with AZT alone or in combination with ddI, ddC, or d4T&#xD;
             for at least 4 weeks unless contraindicated.&#xD;
&#xD;
          -  PCP prophylaxis with TMP/SMX, pentamidine aerosol, dapsone, or atovaquone.&#xD;
&#xD;
          -  MAC prophylaxis with rifabutin or clarithromycin for patients with CD4 count &lt; 100&#xD;
             cells/mm3.&#xD;
&#xD;
          -  Mycobacterium tuberculosis prophylaxis with isoniazid or another accepted regimen for&#xD;
             patients with a positive or previously positive tuberculin test and for anergic&#xD;
             patients who are known household or close contacts of infectious TB patients or who&#xD;
             are from groups in which the prevalence of TB is 10 percent or higher.&#xD;
&#xD;
          -  Investigational drugs unless exempted by protocol chair.&#xD;
&#xD;
          -  Other medications unless expressly prohibited.&#xD;
&#xD;
        Active alcohol or drug abuse.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kalayjian R</last_name>
    <role>Study Chair</role>
  </overall_official>
  <overall_official>
    <last_name>Smith MC</last_name>
    <role>Study Chair</role>
  </overall_official>
  <overall_official>
    <last_name>Lederman M</last_name>
    <role>Study Chair</role>
  </overall_official>
  <location>
    <facility>
      <name>UCLA CARE Center CRS</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ucsf Aids Crs</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harbor-UCLA Med. Ctr. CRS</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana Univ. School of Medicine, Infectious Disease Research Clinic</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Adult AIDS CRS</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Med. Ctr. (Mt. Sinai)</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Case CRS</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MetroHealth CRS</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Kalayjian R, Phinney M, Austen J, Gripshover B, Carey J, Rahman M, Weigel K, Smith MC. Prednisone improves renal function in HIV-associated nephropathy (HIVAN). Natl Conf Hum Retroviruses Relat Infect (2nd). 1995 Jan 29-Feb 2:154</citation>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>October 27, 2021</last_update_submitted>
  <last_update_submitted_qc>October 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AIDS-Related Complex</keyword>
  <keyword>Prednisone</keyword>
  <keyword>AIDS-Associated Nephropathy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>AIDS-Associated Nephropathy</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

